David N. Gill
CIK: 0001106519
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Feb 17, 2026EOLS
Evolus, Inc.
Award(A)Direct45.6K shares- - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Disposition(D)Direct5.8K shares at avg. $8.60$50K - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Disposition(D)Direct25.1K shares- - Jun 30, 2025YMAB
Y-mAbs Therapeutics, Inc.
Award(A)Direct25.1K shares- - Mar 7, 2025EOLS
Evolus, Inc.
Award(A)Direct7.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 17, 2026 |  EOLS Evolus, Inc. | Award(A) | 45,559 | - | $0 | Direct |
| Sep 16, 2025 |  YMAB Y-mAbs Therapeutics, Inc. | Disposition(D) | 5,825 | $8.60 | $50,095 | Direct |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Disposition(D) | 25,080 | - | - | Direct |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Award(A) | 25,080 | - | - | Direct |
| Mar 7, 2025 | EOLS Evolus, Inc. | Award(A) | 7,364 | - | - | Direct |
1-5 of 5 transactions
About GILL DAVID N
GILL DAVID N (SEC CIK 0001106519) files insider reports with the SEC as Director of Telix Pharmaceuticals Ltd (TLX), Director of Evolus, Inc. (EOLS) and Director of Y-mAbs Therapeutics, Inc. (YMAB).
Signal8 holds 5 ownership filings by GILL DAVID N (1 Form 3, 4 Form 4), filed between Mar 11, 2025 and May 18, 2026. Those filings report 5 transactions, from Mar 7, 2025 to Feb 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on GILL DAVID N's filings is in NEWPORT BEACH, CA.
Recent filings by GILL DAVID N
Other insiders filing for Telix Pharmaceuticals Ltd (TLX)
- Smith Darren Charlton, Group Chief Financial Officer
- Jellison William R, Director
- Rivas Maria, Director
- Behrenbruch Christian, MD & Group CEO
- Cade David Norman, Group Chief Medical Officer
- Nelson Mark Alexander, Director